Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa (Q38558538)
Jump to navigation
Jump to search
scientific article published on 29 December 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa |
scientific article published on 29 December 2016 |
Statements
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial (English)
Andrew Blauvelt
Yaung-Kaung Shen
Bruce Randazzo
Yasmine Wasfi